title: Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic treatment. Swiss HIV Cohort Study Group.
abstract: Cytomegalovirus (CMV) retinitis may be treated systemically or intravitreally. We reviewed retrospectively patients with CMV retinitis, in order to determine whether systemic treatment was associated with less spread of CMV retinitis from one eye to the other. Of 222 cases, 92 patients had bilateral disease at onset of CMV retinitis, leaving 130 for analysis. Bilaterality occurred in 10 patients during 12,687 days of systemic treatment and in 34 during 14,791 days without systemic treatment (odds ratio [OR] = 2.92; confidence interval [CI], 1.44-5.90). Patients who had received systemic treatment for <50% of the follow-up period had a greater risk of bilaterality (OR = 3.7; CI, 2.79-4.54) than did the more intensively treated patients. CD4 cell levels also contributed to increased risk, but multivariate analysis showed that CD4 cell counts and treatment intensity were independent risk factors. CMV retinitis was more likely to become bilateral in patients who received less intravenous therapy. Local treatment can complete but does not replace systemically administered therapy.
authors.affiliation: Department of Ophthalmology, University Hospital, Geneva, Switzerland.
authors.forename: N
authors.initials: N
authors.lastname: Stalder
authors.forename: P
authors.initials: P
authors.lastname: Sudre
authors.forename: M
authors.initials: M
authors.lastname: Olmari
authors.forename: M
authors.initials: M
authors.lastname: Opravil
authors.forename: V
authors.initials: V
authors.lastname: Gabriel
authors.forename: A
authors.initials: A
authors.lastname: Sansonetti
authors.forename: J
authors.initials: J
authors.lastname: von Overbeck
authors.forename: C P
authors.initials: CP
authors.lastname: Herbort
authors.forename: B
authors.initials: B
authors.lastname: Hirschel
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D017245:Foscarnet / Q000008:administration & dosage*; D015774:Ganciclovir / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir